At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,501 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Observational Study to Evaluate Medication-taking Behavior With Denosumab (Prolia) and Patient Characteristics in Postmenopausal Women With Osteoporosis in Routine Clinical Practice in Germany, Austria, Greece and Belgium
In Brief
An observational study for Postmenopausal Osteoporosis. Completed, enrolled 1,501 participants across 144 sites in 4 countries.
Detailed Summary
The main objective of this observational study was to describe medication-taking behavior of patients treated with denosumab for postmenopausal osteoporosis (PMO) at 12 and 24 months.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPostmenopausal Osteoporosis
CountriesAustria, Belgium, Germany, Greece
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2011
First PostedAug 2012
Primary CompletionAug 2015
TodayJul 2026
First PostedAug 20, 2012
Enrollment StartNov 28, 2011
Primary CompletionAug 31, 2015
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.9 years ago